Sir -McLoughlin et al.'s recent paper 'Serum and urinary levels of beta human chorionic gonadotrophin in patients with transitional cell carcinoma' (McLoughlin, J., Pepera, T., Bridger, T. & Williams, G., Br. J. Cancer, 1991, 63, 822-824) ; was apparently prompted by my initial paper on expression of P-hCG by .70% of bladder cancer cell lines in vitro (Iles et al., 1987) . As such I feel their results are worthy of further comment.
Their clinical findings were: elevated serum ,B-hCG (>5 mIU ml-1) in only six of 62 patients with elevated urinary levels (>25 mIU ml-') in only three. Unfortunately the stages of disease were not fully documented in the published paper. Of the 13-hCG positive tumour patients, five had 'poorly differentiated' tumours, one with metastatic disease, one extravesical spread, one locally resectable tumour and one clear on cytoscopy. The authors additionally attempted to detect expression of P-hCG by immunohistochemically staining 'representative' sections from 28 tumours. None was found to be positive. Our initial study spurred us on to look at clinical cases. Between 1986 and 1988, pre-treatment blood and/or urine samples were collected from 179 patients attending the Urology Department of the Royal London Hospital. Samples were assayed for ,-hCG immunoreactivity using the in house assay of the department of Reproductive Physiology (St Bartholomew's Hospital) and classified according to the histopathological staging, or clinically where the disease was advanced. The results of this study were published in 1989 (Iles et al., 1989) .
Somewhat in agreement with McLoughlin and colleagues, we found elevated serum P-hCG (>25mIUml') in only two of 55 patients (4%) in whom disease was limited to the renal pelvis (Ta -T4). However, levels were substantially elevated in 16 of 21 patients (76%) with widespread metastatic disease. Furthermore, elevated urinary P-hCG was found in four of 39 TO, 14 of 57 Ta/l, II of 25T2 -T4 patients. Grossly elevated urinary P-hCG levels were detected in 5 of 7 metastatic disease patients.
In total agreement with McLoughlin's preliminary conclusions, P-hCG screening has no value as a general marker of bladder disease. However, ,B-hCG expression is always associated with poor prognosis. Reviewing the literature, which dates from as early as 1904 (Djwetzi, 1904 ; most reports were case studies of advanced stage disease. The more recent studies, principally immunohistochemical, have identified local tumours which expressed P-hCG. All were poorly differentiated (more than 95% G3) and invasive (approximately 60% T3 + ) (Reviewed by Iles & Chard, 1991) . In addition, such expression correlates with those local tumours that do not respond to radiotherapy (Martin et al., 1989) . It is therefore possible that detection of P-hCG expression may identify an aggressive phenotype which is likely to metastasise.
McLoughlin et al.'s failure to detect P-hCG expression by immunohistochemistry may, as they themselves admit, be due to sampling error. It should be borne in mind that hCG and free P-hCG are not stored in secretory granules, being rapidly secreted once synthesised (Handwerger et al., 1987; Corless et al., 1987) . This may well account for the fact that positive sections typically contain only sporadic areas of positive cells. This problem was emphasised by Ryoichi Oyasu (editorial comments to Wurzel et al., 1987) who recommended careful study of serial tumour sections.
It still remains to be determined why normal urothelium produce ,B-hCG in vitro (Iles et al., 1987) . The possibility arises that f3-hCG expression may be characteristic of basal stem cells of the urothelial mucosa (Iles et al., 1990 
